AstraZeneca spins out Albireo
AstraZeneca PLC has spun out its gastrointestinal therapeutics business into a new company called Albireo Pharmaceutical. AZ, along with Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership, provided $27mm in funding to the new entity in a Series A round that is expected to reach $40mm in the near future.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com